These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 25745990)

  • 21. The Impact of Rosuvastatin on the Density Score of Coronary Artery Calcification in Coronary Artery Disease Patients with Type 2 Diabetes Mellitus: Rationale and Design of RosCal Study.
    Zhang W; Luan Y; Jin C; Xu S; Bi X; Zhao Y; Qiu F; Fu G; Wang M
    Clin Drug Investig; 2016 Dec; 36(12):1023-1029. PubMed ID: 27541380
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Statins for the prevention of contrast-induced acute kidney injury.
    Ball T; McCullough PA
    Nephron Clin Pract; 2014; 127(1-4):165-71. PubMed ID: 25343843
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship between inflammation and benefits of early high-dose rosuvastatin on contrast-induced nephropathy in patients with acute coronary syndrome: the pathophysiological link in the PRATO-ACS study (Protective Effect of Rosuvastatin and Antiplatelet Therapy on Contrast-Induced Nephropathy and Myocardial Damage in Patients With Acute Coronary Syndrome Undergoing Coronary Intervention).
    Toso A; Leoncini M; Maioli M; Tropeano F; Di Vincenzo E; Villani S; Bellandi F
    JACC Cardiovasc Interv; 2014 Dec; 7(12):1421-9. PubMed ID: 25523533
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rosuvastatin-induced high-density lipoprotein changes in patients who underwent percutaneous coronary intervention for non-ST-segment elevation acute coronary syndrome.
    Yun KH; Shin SN; Ko JS; Rhee SJ; Kim NH; Oh SK; Jeong JW
    J Cardiol; 2012 Nov; 60(5):383-8. PubMed ID: 22884684
    [TBL] [Abstract][Full Text] [Related]  

  • 25. One-year outcomes of rosuvastatin versus placebo in sepsis-associated acute respiratory distress syndrome: prospective follow-up of SAILS randomised trial.
    Dinglas VD; Hopkins RO; Wozniak AW; Hough CL; Morris PE; Jackson JC; Mendez-Tellez PA; Bienvenu OJ; Ely EW; Colantuoni E; Needham DM
    Thorax; 2016 May; 71(5):401-10. PubMed ID: 26936876
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-Intensity Statins Before Percutaneous Coronary Intervention in Acute Coronary Syndrome-Should It Be Added to Treatment Algorithm?
    Cutlip DE
    Am J Cardiol; 2023 Jun; 196():104-105. PubMed ID: 37059611
    [No Abstract]   [Full Text] [Related]  

  • 27. Do Statins Affect Thyroid Volume and Nodule Size in Patients with Hyperlipidemia in a Region with Mild-to-Moderate Iodine Deficiency? A Prospective Study.
    Demir C; Anil C; Bozkus Y; Mousa U; Kut A; Nar A; Tutuncu NB
    Med Princ Pract; 2018; 27(1):1-7. PubMed ID: 29402848
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of rosuvastatin on platelet-leukocyte interactions in the setting of acute coronary syndrome.
    Sexton TR; Wallace EL; Macaulay TE; Charnigo RJ; Evangelista V; Campbell CL; Bailey AL; Smyth SS
    J Am Coll Cardiol; 2015 Jan; 65(3):306-7. PubMed ID: 25614429
    [No Abstract]   [Full Text] [Related]  

  • 29. Comparative effects of high-dose atorvastatin versus rosuvastatin on lipid parameters, oxidized low-density lipoprotein, and proprotein convertase subtilisin kexin 9 in acute coronary syndrome.
    Altunkeser BB; Tuncez A; Ozturk B; Tezcan H; Ates MS; Yilmaz C; Yalcin MU; Aygul N; Demir K
    Coron Artery Dis; 2019 Jun; 30(4):285-290. PubMed ID: 30741744
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The association of telomere length and telomerase activity with adverse outcomes in older patients with non-ST-elevation acute coronary syndrome.
    Chan D; Martin-Ruiz C; Saretzki G; Neely D; Qiu W; Kunadian V
    PLoS One; 2020; 15(1):e0227616. PubMed ID: 31923255
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimal Medical Therapy in Patients with Malignancy Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndrome: a BleeMACS Sub-Study.
    Iannaccone M; D Ascenzo F; De Filippo O; Gagliardi M; Southern DA; Raposeiras-Roubín S; Abu-Assi E; Henriques JPS; Saucedo J; González-Juanatey JR; Wilton SB; Kikkert WJ; Nuñez-Gil I; Ariza-Sole A; Song X; Alexopoulos D; Liebetrau C; Kawaji T; Huczek Z; Nie SP; Fujii T; Correia L; Kawashiri MA; García-Acuña JM; Alfonso E; Terol B; Garay A; Zhang D; Chen Y; Xanthopoulou I; Osman N; Möllmann H; Shiomi H; Kowara M; Filipiak K; Wang X; Yan Y; Fan JY; Ikari Y; Nakahashi T; Sakata K; Yamagishi M; Moretti C; Gaita F; Kalpak O; Kedev S
    Am J Cardiovasc Drugs; 2017 Feb; 17(1):61-71. PubMed ID: 27738920
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of the intensive dose of rosuvastatin 40mg/day in patients with acute coronary syndrome and at high risk of cardiovascular disease-ROSUVEES-2.
    Shah CP; Shah BP; Dani SI; Channa BB; Lakshmanan SS; Krishnamani NC; Mehta A; Moorthy P
    Indian Heart J; 2016; 68(6):766-771. PubMed ID: 27931543
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rosuvastatin for Reduction of Myocardial Damage during Coronary Angioplasty - the Remedy Trial.
    Briguori C; Madonna R; Zimarino M; Calabrò P; Quintavalle C; Salomone M; Condorelli G; De Caterina R
    Cardiovasc Drugs Ther; 2016 Oct; 30(5):465-472. PubMed ID: 27358173
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial.
    Mora S; Caulfield MP; Wohlgemuth J; Chen Z; Superko HR; Rowland CM; Glynn RJ; Ridker PM; Krauss RM
    Circulation; 2015 Dec; 132(23):2220-9. PubMed ID: 26408274
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Suppressive effects of standard-dose rosuvastatin therapy on the progression of coronary atherosclerosis in Japanese patients: the APOLLO study.
    Amemiya K; Yokoi H; Domei T; Shirai S; Ando K; Goya M; Iwabuchi M
    J Atheroscler Thromb; 2014; 21(12):1298-307. PubMed ID: 25100236
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of lipid-modifying efficacy of rosuvastatin versus atorvastatin in patients with acute coronary syndrome (from the LUNAR study).
    Pitt B; Loscalzo J; Monyak J; Miller E; Raichlen J
    Am J Cardiol; 2012 May; 109(9):1239-46. PubMed ID: 22360820
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of high-dose highly efficient statins on short-term mortality in patients undergoing percutaneous coronary intervention with stenting for acute coronary syndromes.
    Tentzeris I; Rohla M; Jarai R; Farhan S; Freynhofer MK; Unger G; Nürnberg M; Geppert A; Wessely E; Wojta J; Huber K
    Am J Cardiol; 2014 Apr; 113(7):1099-104. PubMed ID: 24462073
    [TBL] [Abstract][Full Text] [Related]  

  • 38. How does lipid lowering prevent coronary events? New insights from human imaging trials.
    Libby P
    Eur Heart J; 2015 Feb; 36(8):472-4. PubMed ID: 25575600
    [No Abstract]   [Full Text] [Related]  

  • 39. Impact of Rosuvastatin on contrast-induced acute kidney injury in patients at high risk for nephropathy undergoing elective angiography.
    Abaci O; Arat Ozkan A; Kocas C; Cetinkal G; Sukru Karaca O; Baydar O; Kaya A; Gurmen T
    Am J Cardiol; 2015 Apr; 115(7):867-71. PubMed ID: 25670636
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Atherosclerosis: Regression of coronary atherosclerosis with statin therapy.
    Huynh K
    Nat Rev Cardiol; 2014 Nov; 11(11):623. PubMed ID: 25245827
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.